Last updated: February 19, 2026
Executive Summary
European Patent EP1830843, titled "DERIVATIVES OF 2-AMINO-4-BENZYLPHENYLACETIC ACID," describes compounds and their use in treating inflammatory diseases. The patent's core innovation lies in a specific chemical structure designed to inhibit cyclooxygenase-2 (COX-2). A comprehensive analysis of its claims and the surrounding patent landscape reveals a mature but potentially contestable patent position, with key implications for generic manufacturers and potential new market entrants.
What are the core claims of EP1830843?
EP1830843 grants exclusive rights over a defined class of chemical compounds and their pharmaceutical applications. The patent's independent claims broadly cover:
-
Compound Claims: Claims 1-12 define specific chemical structures falling under the general formula:
(I)
Ar-CH2-CH(NH2)-COOH
wherein Ar is a substituted benzyl group, with specific substitution patterns defined. This general formula is further refined with sub-formulas (Ia) to (Id) and Markush structures, encompassing a range of related derivatives.
-
Pharmaceutical Compositions: Claims 13-17 claim pharmaceutical compositions comprising at least one compound of formula (I) and a pharmaceutically acceptable carrier, diluent, or excipient. These claims extend to formulations suitable for oral administration.
-
Methods of Treatment: Claims 18-23 cover methods of treating inflammatory conditions by administering a therapeutically effective amount of a compound of formula (I). Specific inflammatory diseases mentioned include arthritis, pain, and fever.
-
Intermediate Compounds: The patent also claims certain intermediate compounds used in the synthesis of the active pharmaceutical ingredients, providing a broader protective scope.
What is the chemical scope of the patented compounds?
The chemical scope of EP1830843 is primarily defined by the general formula (I) and its dependent sub-formulas. The key structural features are:
- 2-Amino-phenylacetic Acid Core: The central moiety is a phenylacetic acid group with an amino substituent at the 2-position.
- Benzyl Substituent (Ar): The critical variation lies in the benzyl group (Ar) attached to the phenyl ring. This benzyl group can be substituted with various functional groups at specific positions.
- Examples of substitutions detailed in the patent: Halogens (F, Cl, Br), alkyl groups (methyl, ethyl), alkoxy groups (methoxy, ethoxy), and nitro groups.
- Specific positions for substitution: The patent delineates that substitutions can occur at the para-position and meta-positions of the phenyl ring within the benzyl group.
The patent includes Markush structures to cover a wider array of potential derivatives that share the core structural elements and the claimed biological activity. This allows for protection beyond precisely enumerated compounds.
What is the mechanism of action and therapeutic indication?
The compounds disclosed in EP1830843 are designed to act as selective cyclooxygenase-2 (COX-2) inhibitors. COX enzymes are responsible for the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever.
- COX-1 vs. COX-2: COX-1 is constitutively expressed in many tissues and plays a role in gastric protection and platelet aggregation. COX-2 is primarily induced at sites of inflammation. Selective COX-2 inhibitors aim to reduce inflammation and pain with a lower risk of gastrointestinal side effects associated with non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that inhibit both COX isoforms.
- Therapeutic Indications: The patent claims utility in treating a range of inflammatory conditions, including but not limited to:
- Arthritis (e.g., osteoarthritis, rheumatoid arthritis)
- Pain (analgesia)
- Fever (antipyresis)
- Inflammatory bowel disease
- Asthma
What is the patent family and filing history?
EP1830843 is part of a broader patent family, indicating an international strategy for protecting the innovation. Key filing and grant details are:
- Application Number: EP 07013999.4
- Priority Date: July 18, 2007
- Filing Date (EPO): July 18, 2007
- Grant Date (EPO): August 12, 2015
- Patent Number: EP 1830843 B1
- Status: Valid and in force in designated European Patent Office (EPO) member states.
- Expiry Date: The patent term for European patents is generally 20 years from the filing date, provided renewal fees are paid. Based on the filing date of July 18, 2007, EP1830843 would have expired on July 18, 2027. (Note: This is subject to individual country validations and potential patent term extensions or restorations, which are not detailed in this analysis).
What is the competitive patent landscape?
The patent landscape surrounding selective COX-2 inhibitors is extensive and complex, reflecting significant research and development in this therapeutic area. EP1830843 operates within a market segment that includes established blockbuster drugs and numerous generic competitors.
Key players and their patented technologies in the COX-2 inhibitor space include (but are not limited to):
- Merck & Co., Inc.: Known for Celecoxib (Celebrex®), which is protected by numerous patents covering composition of matter, methods of use, and polymorphs.
- Pfizer Inc.: Developed Etoricoxib (Arcoxia®) and Rofecoxib (Vioxx®, withdrawn). Patents cover various aspects of these molecules and their therapeutic applications.
- Novartis AG: Has patents related to Lumiracoxib (premax®).
- Bayer AG: Investigated and patented various COX inhibitors.
Analysis of EP1830843's position:
- "Me-too" vs. Novelty: The structure of EP1830843 compounds, specifically the 2-amino-4-benzylphenylacetic acid scaffold, differentiates it from earlier COX-2 inhibitors like celecoxib (a diaryl pyrazole) or etoricoxib (a diaryl pyridine). However, the field of NSAIDs and COX inhibitors is crowded. The novelty and inventiveness of EP1830843's specific substitutions over existing prior art would have been crucial during prosecution.
- Freedom to Operate (FTO): Generic manufacturers seeking to market drugs with similar therapeutic profiles must conduct thorough FTO analyses. This involves assessing whether their proposed product infringes any active patents, including EP1830843 and other patents held by competitors covering compounds, formulations, or methods of use.
- Patent Expiry: While EP1830843 itself has a defined expiry date, its claims might be relevant in the context of challenging older, still-active patents or in developing next-generation compounds that build upon the disclosed scaffolds.
- Potential Litigation: The history of COX-2 inhibitors is marked by significant patent litigation. Any new entrant or generic manufacturer would need to consider the potential for infringement suits. The breadth of the claims in EP1830843 will be a critical factor in such assessments.
What are the key challenges and opportunities?
Challenges:
- Crowded Market: The market for anti-inflammatory drugs is highly competitive, with numerous established and generic options.
- Regulatory Hurdles: New COX-2 inhibitors would face stringent regulatory approval processes, including demonstrating safety and efficacy. The safety profile of earlier COX-2 inhibitors (e.g., Vioxx® withdrawal due to cardiovascular risks) casts a long shadow.
- Prior Art: The extensive patenting in the COX inhibitor space means that identifying truly novel and patentable improvements can be difficult.
- Patent Validity: Broad claims, while offering strong protection, are also more susceptible to invalidation challenges based on prior art or lack of inventive step.
Opportunities:
- Improved Safety Profile: Developing compounds with a demonstrably superior safety profile (e.g., reduced cardiovascular or gastrointestinal risks) compared to existing NSAIDs and selective COX-2 inhibitors represents a significant opportunity.
- New Indications: Exploring novel therapeutic uses or combination therapies that leverage the COX-2 inhibition mechanism could create new market niches.
- Formulation Innovation: Developing advanced drug delivery systems or formulations that enhance efficacy, reduce dosing frequency, or improve patient compliance could provide a competitive edge.
- Targeted Therapies: Further research into specific patient populations who might benefit most from COX-2 inhibition could lead to more personalized treatment approaches.
Key Takeaways
EP1830843 protects a specific class of 2-amino-4-benzylphenylacetic acid derivatives for treating inflammatory conditions, acting as COX-2 inhibitors. The patent family indicates a strategic international filing. With a patent expiry around July 2027, its direct market exclusivity has concluded or is nearing its end, making the landscape ripe for generic competition and FTO analyses for new entrants. The competitive environment for COX-2 inhibitors is mature, with numerous established players and a history of patent litigation. Key opportunities lie in developing compounds with improved safety profiles, exploring new indications, and innovating in drug delivery.
Frequently Asked Questions
-
When does EP1830843 expire?
EP1830843 expired on July 18, 2027, based on its filing date and the standard 20-year patent term.
-
Does EP1830843 cover all COX-2 inhibitors?
No, EP1830843 covers a specific structural class of compounds defined by formula (I) and its dependent claims, not all molecules that inhibit COX-2.
-
Can a company sell a generic version of a drug claimed in EP1830843 after its expiry?
After expiry, generic companies can generally market drugs covered by the patent, provided they do not infringe on other valid, unexpired patents covering formulation, method of use, or related intellectual property.
-
What is the primary therapeutic target of the compounds in EP1830843?
The primary therapeutic target is the inhibition of cyclooxygenase-2 (COX-2) to reduce inflammation, pain, and fever.
-
Are there any known marketed drugs directly derived from EP1830843?
A specific search for drugs directly marketed as being derived solely from EP1830843's disclosed compounds would require access to commercial drug databases and manufacturing information beyond the scope of this patent analysis. However, its patent family suggests it was part of a development pipeline.
Citations
[1] European Patent EP 1830843 B1. (2015). Derivates of 2-amino-4-benzylphenylacetic acid. European Patent Office.
[2] Official Journal of the European Patent Office, Publication Number A1. (Various dates). Information regarding patent family members, filing dates, and grant dates for European Patent Applications. European Patent Office.
